

January 24, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Intimation of Earnings Conference Call for Investors/ Analysts for Q3 & 9M FY25

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Earnings Conference Call for Investors/ Analysts to be held on Thursday, January 30, 2025 at 5:00 P.M. (IST) to discuss the financial and operating performance for Q3 & 9M FY25.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above


Q3 & 9M FY25 Earnings Conference Call Thursday, January 30, 2025 at 5:00pm IST

Gurugram, January 24, 2025:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q3 & 9M FY25 results. DLPL will be represented by (Hony) Brig. Dr. Arvind Lal – Executive Chairman, Dr. Om Prakash Manchanda – Managing Director, Mr. Shankha Banerjee - Chief Executive Officer and Mr. Ved Prakash Goel – Group Chief Financial Officer & CEO – International Business.

The conference call will be initiated with a brief discussion by the management on Q3 & 9M FY25 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none"> ● 5:00pm IST on Thursday, January 30, 2025
Pre-registration	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <div style="text-align: center;">  Click here to ExpressJoin the Call </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Universal Access	<ul style="list-style-type: none"> ● +91 22 6280 1141 ● +91 22 7115 8042
Conference dial-in International Toll Number	<ul style="list-style-type: none"> ● USA – 18667462133 ● UK – 08081011573 ● Singapore – 8001012045 ● Hong Kong – 800964448
Replay	<ul style="list-style-type: none"> ● Dial in No. +91 22 7194 5757 ● 91147# (passcode) ● Valid from Jan 30, 2025 to Feb 05, 2025

-ENDS-

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 343 test panels, 3,075 pathology tests and 1,439 radiology and cardiology tests as on March 31, 2024.

As on March 31, 2024, DLPL's has 280 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). In FY23 & FY24, DLPL collected and processed approximately 72 million samples and 78 million samples from 26.9 million and 27.6 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

For further information, please contact:

Ved P Goel
Dr. Lal PathLabs Limited
E-mail: ved.goel@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki
CDR India
Email: siddharth@cdr-india.com
nishid@cdr-india.com

Disclaimer: Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.